News

Medical device firms tops for job openings (Morning Read)

The latest global hiring report by ZRG Partners found strong hiring demand in medical outsourcing and service sectors — 500 percent more current hiring opportunities than in life science and pharmaceuticals, and 250 percent more than in medical device and supply sectors, based on employee pool size. Medical device firms exceed pharmaceutical, life sciences and outsourcing in the total global hiring requirements.

Highlights of the important and interesting in the world of healthcare:

Wanted: medical service workers. The latest global hiring report by ZRG Partners found strong hiring demand in medical outsourcing and service sectors — 500 percent more current hiring opportunities than in life science and pharmaceuticals, and 250 percent more than in medical device and supply sectors, based on employee pool size. Medical device firms exceed pharmaceutical, life sciences and outsourcing in the total global hiring requirements.

Now, that’s a lot of bandages. Deerfield, Illinois-based Walgreens has struck a strategic alliance with the New York Giants as the football team’s official retail pharmacy. Giants players will hawk flu shots and diabetes testing events. And Walgreens will sponsor New York Giants Youth Football Camps.

Ethics of overseas pediatric trials. A study in Pediatrics finds more pediatric trials are going overseas, notes Pharmalot blogger Ed Silverman. Globalizing pediatric research might reduce the cost and time line for drug development, but will researchers treat the children fairly?

Prescription drug abuse marches higher. Prescription drug abuse has soared to new levels in the last decade despite efforts by most states to curb the abuse, reports Stateline.org.

Mobile application for insulin. Novo Nordisk has launched NovoDose — the first mobile application that enables doctors to properly dose nearly 24 million American diabetics with insulin.

First-in-class. Swiss pharmaceutical giant Roche Holding will pay Cambridge, Massachusetts-based Aileron Therapeutics up to $1.1 billion to develop a new class of drugs to treat cancer, viruses, inflammation, metabolism and central nervous system disorders, according to DailyFinance.

Topics